share_log

Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.

Shares of Companies With Alzheimer's Programs Are Trading After Biogen and Elsai Announced Lecanemab Treatment Its the Primary Endpoint and Reduced Clinical Decline on the Global Cognitive and Functional Scale.

在Biogen和Elsai宣布Lecanemab治疗为主要终点并减少了全球认知和功能量表的临床下降之后,拥有阿尔茨海默氏症项目的公司的股票正在交易。
Benzinga ·  2022/09/28 07:38

Shares of companies with Alzheimer's programs are trading after Biogen and Elsai announced Lecanemab treatment its the primary endpoint and reduced clinical decline on the global cognitive and functional scale.

在Biogen和Elsai宣布Lecanemab治疗为主要终点并减少了全球认知和功能规模的临床下降之后,拥有阿尔茨海默氏症项目的公司的股票正在交易。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发